Correspondingly, reduced CSF levels of Amyloid-beta1-42 (Aβ1-42) and/or elevated CSF levels of total-Tau (t-Tau) and phospho-Tau (p-Tau) have been reported to be associated with cognitive impairment in PD (Brockmann et al. 2015a, 2017; Lerche et al. 2019b; Kang et al. 2016). This evidence concerns the gene MAPT and Cognitive impairment.